SB
Skeletalis Bio develops OASIS, a small‑molecule platform that delivers therapeutics directly to sites of active bone loss while preserving normal bone remodeling. The technology uses osteoclast‑activated targeting to concentrate drug activity where fractures are most likely, aiming to reduce fracture risk across multiple skeletal indications. Commercialization is planned through traditional pharmaceutical licensing and sales of the targeted bone‑health drugs to clinicians and healthcare systems.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Skeletalis Bio develops targeted small-molecule therapies using its Osteoclast-Activated Skeletal Intervention System (OASIS) platform to address musculoskeletal health. This platform concentrates therapeutic activity specifically at sites of active bone loss while preserving the body's natural bone remodeling processes. The company focuses on creating treatments that reduce fracture risk while maintaining healthy skeletal turnover.